COVID-19
The CRF has supported many COVID-19 related studies over the past year. These studies range from investigator led studies where we are trying to understand more about the disease and how it affects people to clinical trials where we are trying to determine the best treatment for patients in either an inpatient or intensive care setting.
| Study Name | Study Title Study | Study Type | Sponsor | Sponsor Type |
|---|---|---|---|---|
| Tropic | Technology Assisted Solutions for the Recognition of Objective Physiological Indicators of post-COVID-19 Fatigue | Obervational (NCT05027724) | Academic | Non Commercial: Academic |
| SOLIDARITY | An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care (Public health emergency SOLIDARITY trial) | Clinical trial (NCT04647669) | WHO | Non-commercial: Hospital |
| Covid Immune response in ICU | Characterising the immune response in Covid-19 infection: towards identifying prognostic indicators of disease severity | Observational | N/A | N/A |
| Sprint-Sari | Short Period Incidence study of severe Acute Respiratory Infection | Observational (NCT02498587) | N/A | N/A |
| STARR Bio-resource | COVID-19 Bioresource Characterising the immune response in Covid-19 infection. | Observational | Academic | Non-commercial: Academic |
| Covid Encephalopathy | Analysing blood-brain barrier integrity to inform on protection from CoVID-19 associated encephalopathy. | Observational | Academic | Non-commercial: Academic |
| EU-SolidAct/Bari-SolidAct | European DisCoVeRy for Solidarity: An Adaptive Pandemic and Emerging Infection Platform Trial / Efficacy and Safety of baricitinib for the treatment of severe COVID-19 | Clinical trial | Oslo University Hospital | Non-commercial: Hospital |
| Discovery | Multi-centre, adaptive, randomised trial of the safety and efficacy of treatments of Covid-19 in hospitalised adults | Clinical trial | National (Government agency) | Non-commercial: Hospital |